Jan 02,2018

Pear Therapeutics Completes $50 Million Series B Financing

PEAR Therapeutics, the leader in prescription digital therapeutics, today announced that it has successfully closed a $50 million Series B financing led by Temasek. With this financing, Temasek joins new and existing investors including 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, Singapore-based EDBI, and the Bridge Builder’s Collaborative. PEAR is the first company to receive U.S. Food and Drug Administration (FDA) clearance for a prescription digital therapeutic with claims to improve clinical outcomes in a disease. The financing will allow the company to commercialize its lead programs and further develop its pipeline and platform.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Feb 28,2018

Japan’s medtech startup CureApp gets $14M to help reduce lifestyle diseases globally

Japan’s digital health startup CureApp announced on Monday that it has fundraised 1.5 billion yen (about $14 million) in the latest round. This follows their previous $3.4 million funding. In addition to existing investors BNV and KII, participating investors in this round are Itochu Corporation (TSE:8001), Itochu Technology Ventures, Cyberdine (TSE:7779), Dai-ichi Life (TSE:8750), Mitsubishi UFJ Capital, Iwagin Jigyo Souzou Capital, Saison Ventures, Chibagin Capital, and Mizuho Capital.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Apr 04,2018

Virta Health Raises $45 Million to Expand Treatment for Type 2 Diabetes Reversal

Virta Health, the first company with a clinically-proven treatment to safely and sustainably reverse type 2 diabetes (T2D) and other chronic metabolic diseases without the use of medications or surgery, announced it has raised a $45 million Series B funding round, bringing the total equity funding to $75 million to date. Key existing investors including Venrock, Obvious Ventures, Creandum, Caffeinated Capital, and Max Levchin’s SciFi VC participated in the round, along with new investors including Founders Fund and Playground Global.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Mar 01,2016

WellDoc partners with J&J's LifeScan, raises $7.5 million more

Baltimore, Maryland-based WellDoc has announced a collaboration with LifeScan, a Johnson and Johnson company that makes blood glucose meters. WellDoc also raised an additional $7.5 million from Johnson & Johnson Innovation and other investors, bringing the company’s total funding in its most recent round to $29.5 million. WellDoc plans to work with LifeScan to integrate BlueStar, an FDA-cleared mobile application and program for people with Type II diabetes, with LifeScan’s OneTouch Verio Flex Bluetooth Smart blood glucose monitoring system and its companion app, OneTouch Reveal mobile app.

FUNDING SERIES B

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 09,2014

Omada Health Closes $23 Million Series B Financing Led by Andreessen Horowitz

Omada Health, a pioneer in the emerging field of digital therapeutics, today announced it has closed $23 million in Series B financing led by Andreessen Horowitz, with participation from Kaiser Permanente Ventures and existing investors including U.S. Venture Partners and The Vertical Group. In addition, Andreessen Horowitz general partner, Balaji S. Srinivasan, will be joining Omada Health’s board of directors.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Sep 04,2014

Propeller Health Raises $14.5 Million Series B Financing Led by Safeguard Scientifics

Propeller Health, the FDA-cleared digital health solution for chronic respiratory disease, today announced that it raised $14.5 million in Series B financing, led by Safeguard Scientifics (NYSE:SFE) with participation from Series A investor The Social+Capital Partnership. Propeller Health will use the funding to accelerate product development, strategic alliances, client services, sales and marketing.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
May 05,2022

Digital therapeutics firm Sidekick lands $55M in Series B round

The firm plans to expand its chronic disease treatments across more therapeutic areas.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Jul 19,2021

Digital addiction treatment company Quit Genius scores $64M

Quit Genius, a digital treatment platform for addiction, closed a $64 million Series B funding round. The round was co-led by Kinnevik and Atomico, with additional participation from Octopus Ventures, Triple Point Ventures and Startup Health. This, in addition to the company's Series A round from last year, brings its total amount raised to $77.5 million.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Jul 21,2021

Woebot Health Closes $90 Million Series B Funding Round Co-Led by JAZZ Venture Partners and Temasek

Woebot Health today announced it has closed a $90 million Series B funding round, bringing total investment in the company to $114 million. The round was co-led by existing investor JAZZ Venture Partners and Temasek with participation from funds and accounts managed by BlackRock Private Equity Partners and Owl Ventures. Additional participants include Mirae Asset Capital, Kicker Ventures, Alumni Ventures and Gaingels as well as existing investors NEA and AI Fund. Woebot Health will use the proceeds to accelerate further development of its relational platform and technologies, advance its lead digital therapeutic candidates, and expand its team and go-to-market activities to meet surging global demand for mental health care.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Jul 28,2021

MedRhythms Closes $25M Series B Funding Led by Morningside Ventures and Advantage Capital to Advance Digital Therapeutics Platform

MedRhythms, a leader in developing prescription digital therapeutics that use sensors, software, and music to measure and improve walking for patients with a neurologic injury or disease, announced today the closing of a $25 million Series B financing round co-led by Morningside Ventures and Advantage Capital, with participation from existing investor Werth Family Investment Associates. The Company has raised a total of $34 million in gross proceeds from private financings since inception.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Subscribe to SERIES B